Pharmaceutical

Mapi Pharma to Present Plans for Additional Studies of GA Depot in Multiple Sclerosis and Other Indications and Highlight Latest Results on GA Depot in Relapsing Multiple Sclerosis at the ECTRIMS-ACTRIMS® Meeting in Milan, Italy October 11-13, 2023

Staff October 10, 2023

Meeting to feature latest clinical findings on GA Depot and showcase commitment to improving care for people living with multiple...

Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions

Staff October 10, 2023

BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical...

American Journal of Respiratory and Critical Care Medicine Publishes Full, Positive Results of Apnimed’s MARIPOSA Study on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea

Staff October 10, 2023

-- Phase 3 Clinical Trials for AD109 Currently Enrolling Patients in the U.S.CAMBRIDGE, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) --...

Trinity Biotech Welcomes The Decision Of The High Court Of Kenya To Strike Out The Applications To Prevent the Procurement of TrinScreen HIV By The Kenyan Ministry of Health

Staff October 10, 2023

DUBLIN, Ireland, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer...

Helsinn closes financing agreement with BancaStato to support business objectives and growth

Staff October 10, 2023

Helsinn closes financing agreement with BancaStato to support business objectives and growth New funding secured to expand the portfolio of...

Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society’s Annual Meeting at ObesityWeek ®

Staff October 10, 2023

BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...

Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit

Staff October 10, 2023

NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines...

PetVivo Holdings, Inc. to Exhibit at 2023 American College of Veterinary Surgeons Conference

Staff October 10, 2023

MINNEAPOLIS, MN, US, Oct. 10, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging...

Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors

Staff October 10, 2023

-- Enhances diversity and expertise in key areas including scientific, commercial, and financial -- TAMPA, Fla., Oct. 10, 2023 (GLOBE...

ORYZON presents blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder

Staff October 10, 2023

At the 36th European College of Neuropsychopharmacology congress (ECNP-2023)MADRID, Spain and BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics,...

Kamada Provides Corporate Update on its Israel Operations

Staff October 10, 2023

REHOVOT, Israel, and HOBOKEN, N.J., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage...

BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Staff October 10, 2023

- In our study, encaleret restored physiologic mineral homeostasis in 13 participants with ADH1, specifically correcting hypocalcemia and reducing hypercalciuria...

Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director

Staff October 10, 2023

Christal Mickle transitions back to Chief Development Officer CELEBRATION, Fla., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS:...

Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17th

Staff October 10, 2023

WARRINGTON, Pa., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...

Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer

Staff October 10, 2023

Dr. Gardner brings over 30 years of experience leading clinical development to support innovative oncology programs and translational research at...

Fortrea’s Jim Cameli Named a Top 100 Global Chief Information Security Officer by HotTopics

Staff October 10, 2023

DURHAM, N.C., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced...

Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction

Staff October 10, 2023

Results Demonstrate the Active Pharmaceutical Ingredient in Cardiol's Novel CRD-38 Formulation Attenuates Harmful Fat Distribution and Key Markers of Cardiac...

Relief Therapeutics Announces that more than 400,000 of its ADRs are Currently Outstanding and that, as a Result, the Company has Achieved an Important NASDAQ Initial Listing Milestone

Staff October 10, 2023

GENEVA, SWITZERLAND / ACCESSWIRE / October 10, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical...

IRLAB Signs Phase III Regulatory US Consultants to Support Preparation for Mesdopetam’s end-of-Phase 2 Meeting with the US FDA

Staff October 10, 2023

GOTHENBURG, SWEDEN / ACCESSWIRE / October 10, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company...

Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023

Staff October 9, 2023

ENGLEWOOD, CO / ACCESSWIRE / October 9, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company...

Pharmaceutical

Mapi Pharma to Present Plans for Additional Studies of GA Depot in Multiple Sclerosis and Other Indications and Highlight Latest Results on GA Depot in Relapsing Multiple Sclerosis at the ECTRIMS-ACTRIMS® Meeting in Milan, Italy October 11-13, 2023

Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions

American Journal of Respiratory and Critical Care Medicine Publishes Full, Positive Results of Apnimed’s MARIPOSA Study on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea

Trinity Biotech Welcomes The Decision Of The High Court Of Kenya To Strike Out The Applications To Prevent the Procurement of TrinScreen HIV By The Kenyan Ministry of Health

Helsinn closes financing agreement with BancaStato to support business objectives and growth

Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society’s Annual Meeting at ObesityWeek ®

Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit

PetVivo Holdings, Inc. to Exhibit at 2023 American College of Veterinary Surgeons Conference

Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors

ORYZON presents blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder

Kamada Provides Corporate Update on its Israel Operations

BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director

Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17th

Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer

Fortrea’s Jim Cameli Named a Top 100 Global Chief Information Security Officer by HotTopics

Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction

Relief Therapeutics Announces that more than 400,000 of its ADRs are Currently Outstanding and that, as a Result, the Company has Achieved an Important NASDAQ Initial Listing Milestone

IRLAB Signs Phase III Regulatory US Consultants to Support Preparation for Mesdopetam’s end-of-Phase 2 Meeting with the US FDA

Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023

A Year of Purpose and Progress: Dr. Christina Rahm Celebrates Global Growth, Scientific Breakthroughs, and International Honors

Waters Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026

NAVER D2SF-Backed Startups Participate in “CES 2026”

Next Gen Diagnostics Launches NGD Infection Prevention to Provide Real-Time Transmission Detection

Historic $15 Million Gift Fuels Breakthrough Cancer Care at Hartford HealthCare St. Vincent’s Medical Center

You may have missed